The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Jan 2003
Randomized Controlled Trial Multicenter Study Clinical TrialOmalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma.
Prevention of serious asthma exacerbations is an important therapeutic goal in patients with asthma. ⋯ Omalizumab reduces the rate of serious asthma exacerbations and the need for unscheduled outpatient visits, emergency room treatment, and hospitalization in patients with moderate-to-severe allergic asthma.
-
J. Allergy Clin. Immunol. · May 2001
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialAddition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations.
Adding salmeterol to low-dose fluticasone propionate (FP) produces greater improvements in pulmonary function and symptom control than increasing the dose of FP in patients who remain symptomatic with low-dose FP. ⋯ Salmeterol plus low-dose FP was more effective than higher dose FP alone in reducing asthma exacerbations in patients with persistent asthma. The ability to detect deteriorating asthma and the severity of exacerbation was similar between groups.
-
J. Allergy Clin. Immunol. · Dec 2000
Multicenter Study Clinical Trial Controlled Clinical TrialFluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast.
Asthma is a disease of chronic inflammation and bronchoconstriction. Inhaled corticosteroids (ICSs) provide important anti-inflammatory treatment but may not provide optimal control of asthma when taken alone. Two therapeutic alternatives for enhanced asthma control are to substitute the combination of fluticasone propionate (FP) and salmeterol (FP/Salm Combo) through the Diskus inhaler or to add montelukast to existing ICS therapy. ⋯ Symptomatic patients on low-dose ICS therapy had significantly greater improvement in asthma control when switched to the FP/Salm Combo than when montelukast was added to ICS therapy.
-
J. Allergy Clin. Immunol. · Nov 2000
Randomized Controlled Trial Multicenter Study Clinical TrialMulticenter, double-blind, placebo-controlled, multiple-challenge evaluation of reported reactions to monosodium glutamate.
The frequency of reactions reported to occur after the consumption of monosodium glutamate (MSG) is the subject of controversy. ⋯ The results suggest that large doses of MSG given without food may elicit more symptoms than a placebo in individuals who believe that they react adversely to MSG. However, neither persistent nor serious effects from MSG ingestion are observed, and the responses were not consistent on retesting.
-
J. Allergy Clin. Immunol. · Mar 2000
Multicenter Study Clinical Trial Controlled Clinical TrialHazelnut allergy: a double-blind, placebo-controlled food challenge multicenter study.
Tree nuts are a common cause of food allergy in Europe. However, few studies deal with real food allergy to hazelnuts in subjects believed to be allergic to this food. ⋯ This study shows that hazelnut is an allergenic source that can cause real food allergy, as confirmed by DBPCFC. Skin and IgE tests demonstrated reasonable sensitivity and PPV but a very low specificity and NPV, thus implying that these should not be used to validate the diagnosis of food allergy to hazelnut.